The cPass test kit (Photo: Genscript Biotech Corporation) Singapore (VNA) – Singapore has successfully developed a quick test kit for the COVID-19 which shows result within one hour.
The kit, known as cPass, is used to seek potential vaccine against the SARS-CoV-2 that causes the disease, check what proportion of the population has already been infected, and for contact tracing, which is critical as Singapore eases up on circuit breaker measures.
The advantages of the new test over others currently being used are that it is fast, can single out antibodies, and can be used in regular research or hospital settings rather than needing specialised expertise and equipment.
It will be developed by experts of the Duke-NUS Medical School in collaboration with biotech company GenScript Biotech Corporation and the Agency for Science, Technology and Research's (A*Star) Diagnostics Development Hub (DxD Hub)./.
